The Board of Jintian Pharmaceutical Group Limited announced the shareholders and the potential investors that, based on the preliminary review and assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2014, the Group is expected to record an increase of not less than 30% in its consolidated net profit attributable to owners of the company for the year ended 31 December 2014 as compared with that for the year ended 31 December 2013. The substantial increase is mainly attributable to the significant growth in both the retail and distribution businesses of the Group.